Pro-Dex (NASDAQ:PDEX) CEO Kirk Richard Lee Van, Jr. Sells 4,128 Shares

Pro-Dex, Inc. (NASDAQ:PDEX) CEO Kirk Richard Lee Van, Jr. sold 4,128 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $62.36, for a total transaction of $257,422.08. Following the transaction, the chief executive officer owned 89,707 shares of the company’s stock, valued at $5,594,128.52. This trade represents a 4.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pro-Dex Stock Up 2.6%

NASDAQ PDEX traded up $1.63 on Tuesday, hitting $65.15. 55,396 shares of the stock were exchanged, compared to its average volume of 29,868. The company has a quick ratio of 2.14, a current ratio of 3.67 and a debt-to-equity ratio of 0.32. Pro-Dex, Inc. has a fifty-two week low of $23.47 and a fifty-two week high of $65.88. The company has a market cap of $207.83 million, a PE ratio of 18.00 and a beta of -0.12. The company has a 50-day moving average price of $53.42 and a 200-day moving average price of $44.58.

Pro-Dex (NASDAQ:PDEX) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.58. Pro-Dex had a net margin of 16.08% and a return on equity of 22.78%. The business had revenue of $19.95 million during the quarter, compared to analysts’ expectations of $17.90 million. Sell-side analysts anticipate that Pro-Dex, Inc. will post 3.16 EPS for the current fiscal year.

Institutional Trading of Pro-Dex

Several institutional investors and hedge funds have recently bought and sold shares of PDEX. Los Angeles Capital Management LLC purchased a new stake in Pro-Dex in the 4th quarter valued at $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Pro-Dex in the 2nd quarter valued at $50,000. AlphaQuest LLC purchased a new stake in Pro-Dex in the 3rd quarter valued at $71,000. Bank of America Corp DE raised its position in Pro-Dex by 173.3% in the 2nd quarter. Bank of America Corp DE now owns 1,692 shares of the medical instruments supplier’s stock valued at $74,000 after purchasing an additional 1,073 shares during the last quarter. Finally, Wells Fargo & Company MN raised its position in Pro-Dex by 65.4% in the 4th quarter. Wells Fargo & Company MN now owns 2,314 shares of the medical instruments supplier’s stock valued at $89,000 after purchasing an additional 915 shares during the last quarter. Hedge funds and other institutional investors own 15.28% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Ascendiant Capital Markets upped their target price on shares of Pro-Dex from $56.00 to $70.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Weiss Ratings restated a “hold (c+)” rating on shares of Pro-Dex in a report on Friday, May 1st. Finally, Zacks Research upgraded shares of Pro-Dex to a “hold” rating in a report on Tuesday, May 19th. One investment analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $70.00.

Pro-Dex Company Profile

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.